Literature DB >> 19104903

Debate: Resection for early hepatocellular carcinoma.

Timothy M Pawlik1.   

Abstract

The management of patients with cirrhosis and early hepatocellular carcinoma (HCC) meeting the Milan criteria is controversial. Although liver transplantation for early HCC has been shown to have excellent long term survival rates and low recurrence rates, its application is limited by organ availability. Hepatic resection is an alternative therapy for early HCC. Hepatic resection can be performed safely in patients with early HCC and well-compensated cirrhosis. In addition, the reported 5-year survival rates are in the range of 50%. Resection may also allow a better understanding of tumor biology through pathologic examination of the specimen while also providing a potentially curative therapeutic option. The management of patients with early HCC is complex. Resection should not be viewed as opposing transplantation. Rather, hepatic resection should be seen as complementary to transplantation. The best therapeutic strategies for patients with early HCC and well-compensated cirrhosis should be dependent on the individual clinical situation, not adherence to dogmatic universal adoption of either resection or transplantation.

Entities:  

Mesh:

Year:  2008        PMID: 19104903     DOI: 10.1007/s11605-008-0779-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  10 in total

1.  High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.

Authors:  Margarita Sala; Josep Fuster; Josep M Llovet; Miquel Navasa; Manel Solé; María Varela; Fernando Pons; Antoni Rimola; Juan Carlos García-Valdecasas; Concepció Brú; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-10       Impact factor: 5.799

2.  Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.

Authors:  Ronnie Tung-Ping Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; John Wong
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

3.  Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis.

Authors:  Alessandro Cucchetti; Giorgio Ercolani; Marco Vivarelli; Matteo Cescon; Matteo Ravaioli; Giuliano La Barba; Matteo Zanello; Gian Luca Grazi; Antonio Daniele Pinna
Journal:  Liver Transpl       Date:  2006-06       Impact factor: 5.799

4.  Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation.

Authors:  Charles H Cha; Leyo Ruo; Yuman Fong; William R Jarnagin; Jinru Shia; Leslie H Blumgart; Ronald P DeMatteo
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

Review 5.  Treatment before liver transplantation for HCC.

Authors:  J Belghiti; B I Carr; P D Greig; R Lencioni; R T Poon
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344

6.  Resection prior to liver transplantation for hepatocellular carcinoma.

Authors:  Jacques Belghiti; Alexandre Cortes; Eddie K Abdalla; Jean-Marc Régimbeau; Kurumboor Prakash; François Durand; Daniele Sommacale; Federica Dondero; Mickael Lesurtel; Alain Sauvanet; Olivier Farges; Reza Kianmanesh
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

7.  Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective.

Authors:  F P Sarasin; E Giostra; G Mentha; A Hadengue
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

8.  An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution.

Authors:  Shimul A Shah; Sean P Cleary; Jensen C C Tan; Alice C Wei; Steve Gallinger; David R Grant; Paul D Greig
Journal:  Ann Surg Oncol       Date:  2007-05-24       Impact factor: 5.344

9.  Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection.

Authors:  R Izumi; K Shimizu; T Ii; M Yagi; O Matsui; A Nonomura; I Miyazaki
Journal:  Gastroenterology       Date:  1994-03       Impact factor: 22.682

10.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.

Authors:  Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

  10 in total
  2 in total

1.  Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy.

Authors:  David D Aufhauser; Eran Sadot; Douglas R Murken; Kevin Eddinger; Maarouf Hoteit; Peter L Abt; David S Goldberg; Ronald P DeMatteo; Matthew H Levine
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

2.  Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.

Authors:  Yang Xu; Venugopal Chenna; Chaoxin Hu; Hai-Xiang Sun; Mehtab Khan; Haibo Bai; Xin-Rong Yang; Qin-Feng Zhu; Yun-Fan Sun; Anirban Maitra; Jia Fan; Robert A Anders
Journal:  Clin Cancer Res       Date:  2011-08-25       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.